The Finnish Medicines Agency Fimea has approved Tenboron’s Phase I clinical trial application.
The study will be conducted at the Helsinki University Hospital.
Preparations for study initiation are underway.
The Finnish Medicines Agency Fimea has approved Tenboron’s Phase I clinical trial application.
The study will be conducted at the Helsinki University Hospital.
Preparations for study initiation are underway.
Potential
Has been in previous studies curative for 15-20% of terminal phase patients, despite using sub-optimal boron carrier
Can be used to treat many kinds of solid tumors that can be boron loaded
Affects healthy tissues less than conventional radiation therapy
Can be used in combination with other treatments
Cost-effective
Low number of treatment sessions
Short hospital period – outpatient in many cases
Can be repeated
Dr. Timo Veromaa,
Chairman
Dr. Anu Muona,
Board Member
Mr. Juhani Saarinen,
Board Member
Dr. Seppo Pakkala,
Board Member and Chief Medical Officer
Mr. Juha Jouhki,
Chief Executive Officer
Partner: Glykos Finland Ltd.
Dr. Jari Helin,
Head of CMC
Dr. Jukka Hiltunen,
Project manager
Ms. Sirkku Holttinen,
Quality Assurance Manager